Atopic Dermatitis News and Research

RSS
Atopic dermatitis is a long-term skin disease. "Atopic" refers to a tendency to develop allergy conditions. "Dermatitis" means swelling of the skin. Atopic dermatitis is most common in babies and children. But it can happen to anyone. People who live in cities and dry climates may be more likely to get this disease. When children with atopic dermatitis grow older, this problem can improve or go away. But the skin may stay dry and easy to irritate. At other times, atopic dermatitis is a problem in adulthood. You can't "catch" the disease or give it to other people.
Provectus Pharmaceuticals receives $7.5M in private placement offering

Provectus Pharmaceuticals receives $7.5M in private placement offering

Scientists identify  EoE-associated region in human chromosome

Scientists identify EoE-associated region in human chromosome

Pediatrics researchers identify major gene location responsible for EoE

Pediatrics researchers identify major gene location responsible for EoE

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

Overview of nanotechnology: Nanoparticles may eventually be used in cosmetic products

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation

Onset Therapeutics expands its sales force to create nationwide presence

Onset Therapeutics expands its sales force to create nationwide presence

NTNU: 40% of two-year-olds report allergy-related disorders

NTNU: 40% of two-year-olds report allergy-related disorders

PhotoMedex regains compliance with Nasdaq minimum bid price requirement

PhotoMedex regains compliance with Nasdaq minimum bid price requirement

Study identifies new mechanism that causes allergic response in people

Study identifies new mechanism that causes allergic response in people

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

PhotoMedex, Galderma Laboratories enter into co-promotion agreement for photodynamic therapy application

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

Hi-Tech Pharmacal receives clearance from FDA to market Tropazone lotion

ZymoGenetics announces pricing of public offering of 14,000,000 shares

ZymoGenetics announces pricing of public offering of 14,000,000 shares

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Enrollment of patients for Phase IIb clinical trial of WBI-1001 commenced

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Positive results from DermaGen's Phase I/IIa AMP study of atopic dermatitis

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials

Positive data from Provectus Pharmaceuticals' psoriasis and atopic dermatitis trials